Scarica l'app Stockscreener
1.63
1.24%
0.02
Dopo l'orario di chiusura:
1.63
Precedente Chiudi:
$1.61
Aprire:
$1.6
Volume 24 ore:
1.68M
Relative Volume:
3.74
Capitalizzazione di mercato:
$68.85M
Reddito:
$88.55M
Utile/perdita netta:
$-53.21M
Rapporto P/E:
-1.2598
EPS:
-1.2939
Flusso di cassa netto:
$-29.48M
1 W Prestazione:
+39.32%
1M Prestazione:
+25.38%
6M Prestazione:
-0.61%
1 anno Prestazione:
-11.41%
Intervallo 1D:
$1.51
$1.85
Intervallo di 1 settimana:
$1.18
$1.85
Portata 52W:
$1.13
$2.89
Pulmonx Corp Stock (LUNG) Company Profile
Nome
Pulmonx Corp
Settore
Industria
Telefono
650-364-0400
Indirizzo
700 CHESAPEAKE DRIVE, REDWOOD CITY
Compare LUNG vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LUNG
Pulmonx Corp
|
1.63 | 51.53M | 88.55M | -53.21M | -29.48M | -1.2939 |
ABT
Abbott Laboratories
|
105.74 | 182.00B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
325.74 | 129.09B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
85.40 | 107.81B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
46.73 | 67.64B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.03 | 47.81B | 6.30B | 1.07B | 1.09B | 1.8406 |
Pulmonx Corp Stock (LUNG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-31 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2025-03-10 | Iniziato | D. Boral Capital | Buy |
| 2024-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2024-06-04 | Iniziato | Lake Street | Buy |
| 2024-02-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-09-05 | Iniziato | Craig Hallum | Buy |
| 2023-02-27 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-01-03 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-12-12 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-07-11 | Downgrade | Citigroup | Buy → Neutral |
| 2022-03-02 | Ripresa | BofA Securities | Neutral |
| 2021-12-08 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-04-01 | Iniziato | Citigroup | Buy |
| 2021-03-25 | Iniziato | Piper Sandler | Neutral |
| 2021-03-10 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-10-26 | Iniziato | BofA Securities | Buy |
| 2020-10-26 | Iniziato | Canaccord Genuity | Buy |
| 2020-10-26 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-10-26 | Iniziato | Stifel | Buy |
| 2020-10-26 | Iniziato | Wells Fargo | Equal Weight |
Mostra tutto
Pulmonx Corp Borsa (LUNG) Ultime notizie
LUNG|Pulmonx Corp|Price:1.225|Chg%:+0.055 - TradingKey
Pulmonx Corp (LUNG) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pulmonx Corp expected to post a loss of 28 cents a shareEarnings Preview - TradingView
Pulmonx Reports Q1 2026 Earnings with Strategic Outlook - Intellectia AI
Pulmonx Market Sentiment - Benzinga España
Pulmonx Corp. Revenue Breakdown – MUN:4NI - TradingView
Pulmonx Corp (LUNG) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Pulmonx Corp (LUNG) Valuation: PE, PB & Fair Value Analysis - TradingKey
Pulmonx Corp (LUNG) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pulmonx Corp (LUNG) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Pulmonx Corp (LUNG) Cash Flow - TradingKey
TradingKey - TradingKey
Pulmonx Sets July 29 Webcast to Discuss Second-Quarter Results - Stock Titan
Pulmonx Corp (LUNG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pulmonx (NASDAQ:LUNG) Sparks Fresh Penny Stock Buzz - Kalkine Media
Pulmonx Corp highlights lung device strategy as a specialized medtech player - ad-hoc-news.de
Enterprise value to EBIT forward of Pulmonx Corporation – NASDAQ:LUNG - TradingView
Enterprise value to EBITDA forward of Pulmonx Corp. – LSX:A2P1AF - TradingView
Price to earnings forward of Pulmonx Corp. – LSX:A2P1AF - TradingView
Price to sales forward of Pulmonx Corp. – DUS:4NI - TradingView
Pulmonx Corp highlights its respiratory device portfolio as investors assess long-term growth prospe - Ad Hoc News
LUNG News | PULMONX CORP (NASDAQ:LUNG) - ChartMill
Pulmonx Corp. Actuals & Estimates (NASDAQ:LUNG) - TradingView
Pulmonx Corp (LUNG) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Pulmonx Corp (LUNG) Institutional Confidence - TradingKey
Pulmonx Corp (LUNG) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
LUNG SEC FilingsPulmonx Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Pulmonx (LUNG) awards 40,000 restricted stock units to director - Stock Titan
Director Ferrari (LUNG) awarded 40,000 Pulmonx restricted stock units - Stock Titan
Pulmonx Corp (LUNG) director granted 40,000 restricted stock units - Stock Titan
[Form 4] Pulmonx Corp Insider Trading Activity - Stock Titan
Pulmonx (LUNG) director receives 40,000-share RSU stock grant - Stock Titan
Don't Ignore The Insider Selling In Pulmonx - Sahm
Pulmonx (NASDAQ: LUNG) investors back board, auditor and executive pay - Stock Titan
Pulmonx general counsel David Lehman sells $22,474 in stock - Investing.com UK
Pulmonx general counsel David Lehman sells $22,474 in stock By Investing.com - Investing.com India
Pulmonx (LUNG) officer sells 14,497 shares to cover RSU tax withholding - Stock Titan
Pulmonx (LUNG) General Counsel sells 14,594 shares to cover RSU tax obligations - Stock Titan
Pulmonx (LUNG) CCO sells shares to cover RSU tax obligations - Stock Titan
Pulmonx (LUNG) CEO logs 56K-share sale tied to RSU tax withholding - Stock Titan
Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
17 Pulmonx hires receive 84,300 RSUs in Nasdaq inducement plan - Stock Titan
Pulmonx (LUNG) Q1 2026 Earnings Transcript - AOL.com
LUNGPulmonx Corp Stock Price and Quote - Finviz
QTEX Stock Price and Chart — NASDAQ:QTEX - TradingView
Pulmonx (LUNG) Holds Steady Near $1.54 as Key Support and Resistance Levels Define Trading RangeProtective Put - The Legal Advocate
Pulmonx Corp stock (US74586W1018): Q1 2026 results highlight growth path in minimally invasive lung - AD HOC NEWS
Pulmonx Corp stock (US74586W1018): credit line and margin focus keep lung care specialist in the spo - AD HOC NEWS
LUNG Technical Analysis | Trend, Signals & Chart Patterns | PULMONX CORP (NASDAQ:LUNG) - ChartMill
Why Pulmonx Corporation (LUNG) valuation makes sense when you dig deeper (Marginal Loss) 2026-05-11Buffered ETF - Newser
Pulmonx Corp Azioni (LUNG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Pulmonx Corp Azioni (LUNG) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Lehman David Aaron | GENERAL COUNSEL |
Jun 01 '26 |
Sale |
1.54 |
14,594 |
22,475 |
376,161 |
| Rose Geoffrey Beran | CHIEF COMMERCIAL OFFICER |
Jun 01 '26 |
Sale |
1.54 |
8,023 |
12,355 |
457,711 |
| French Glendon E. III | President and CEO |
Jun 01 '26 |
Sale |
1.54 |
42,638 |
65,663 |
1,191,673 |
| French Glendon E. III | President and CEO |
Jun 02 '26 |
Sale |
1.57 |
13,511 |
21,212 |
1,178,162 |
| Radhakrishnan Srikanth | Chief Science &Techn. Officer |
Mar 02 '26 |
Sale |
1.43 |
10,483 |
14,991 |
170,736 |
| French Glendon E. III | President and CEO |
Mar 02 '26 |
Sale |
1.43 |
67,813 |
96,973 |
1,409,511 |
| Rose Geoffrey Beran | CHIEF COMMERCIAL OFFICER |
Mar 02 '26 |
Sale |
1.43 |
7,732 |
11,057 |
365,734 |
| Lehman David Aaron | GENERAL COUNSEL |
Mar 02 '26 |
Sale |
1.43 |
12,237 |
17,499 |
240,755 |
1.04%
11.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):